Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOMNART
PACTR202609890916410Phase 4Not yet recruiting
- Sponsor
- Wits Health Consortium
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in human immunodeficiency virus infection (HIV) comparing Switch to Delstrigo with Continue TLD (2 arms). Primary endpoint: Change in RU-SATED total score from baseline to week 12. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
doravirinedolutegravir + tenofovir disoproxil fumarate + lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202609890916410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202609890916410.